SecBot SecBot
8-K ·Filed Mar 4, 2026

OCGN

Ocugen, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago SEC0001104659-26-023288
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor upcoming clinical data readouts for OCU400 (Q1 2027) and OCU410 (March 2026), which could be catalysts. The extended cash runway into Q4 2026 reduces near-term dilution risk, but investors should watch for potential warrant exercises from the Janus Henderson financing that could extend funding into Q2 2027.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.96
T+0 close · Mar 4, 2026 · via day close
Latest settled
−28.06%
T+60 · $1.41
Vs SPY
−38.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 4 $1.96entry
  2. T+1 · 9mo ago −11.22%α −10.65% · $1.74
  3. T+5 · 8mo ago +17.35%α +18.68% · $2.30
  4. T+20 · 8mo ago −8.67%α −4.26% · $1.79
  5. T+60 · 6mo ago −28.06%α −38.15% · $1.41
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocugen reported financial results for Q4 and full year 2025, showing increased R&D spending and net losses, but highlighted significant clinical progress including completed enrollment in its OCU400 Phase 3 trial and positive preliminary data for OCU410. The company secured $22.5 million in financing to extend its cash runway into Q4 2026.

Key Financial Metrics

Revenue
-$193.0K
EPS
$-6.00

Key Facts

  • Completed enrollment in OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa; topline data expected Q1 2027
  • Positive preliminary Phase 2 data for OCU410 in geographic atrophy showed 46% lesion growth reduction
  • Secured $22.5 million in gross proceeds through a registered direct offering in January 2026
  • Cash and restricted cash totaled $18.9 million as of December 31, 2025, down from $58.8 million a year earlier
  • Reported net loss of $0.06 per share in Q4 2025, compared to $0.05 per share in Q4 2024

Financial Impact

Net loss increased to $17.7 million in Q4 2025 from $13.9 million in Q4 2024, with cash declining by $39.9 million year-over-year

cashnet lossR&D expenses

Risk Factors

  • Cash position decreased significantly from $58.8 million to $18.9 million year-over-year, despite recent financing
  • Net losses increased year-over-year, with R&D expenses rising from $32.1 million in 2024 to $39.8 million in 2025
  • Future funding remains dependent on warrant exercises and potential partnerships

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-023288
Document: tm267731d1_ex99-2.htm0001104659-26-023288
Document: tm267731d1_8k.htm0001104659-26-023288
Document: 0001104659-26-023288-index-headers.html0001104659-26-023288
Document: 0001104659-26-023288-index.html0001104659-26-023288
Document: 0001104659-26-023288.txt0001104659-26-023288

Track record

23 reports on OCGN

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  2. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  3. Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  4. Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
  7. Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  8. Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  9. Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 4, 2026